FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Margaret Brousseau

Research Profile

Chemicals & Drugs

Disorders

Physiology

Genotype

Co-author Network

Publications

TOP 3
Margaret R Diffenderfer; Gregory G Dolnikowski; John S Millar; Chorthip Nartsupha; Daniel J Rader; P Hugh R Barrett; Margaret E Brousseau; Peter M Schaefer; Megan L Wolfe; Ernst J Schaefer
Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.
Margaret E Brousseau; John S Millar; Margaret R Diffenderfer; Chorthip Nartsupha; Bela F Asztalos; Megan L Wolfe; James P Mancuso; Andres G Digenio; Daniel J Rader; Ernst J Schaefer
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.
John S Millar; Margaret E Brousseau; Margaret R Diffenderfer; Hugh Barrett; Francine K Welty; Jeffrey S Cohn; Aisha Wilson; Megan L Wolfe; Chorthip Nartsupha; Peter M Schaefer; Andres G Digenio; James P Mancuso; Gregory G Dolnikowski; Ernst Schaefer; Daniel J Rader
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Margaret Brousseau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Margaret R Diffenderfer; Gregory G Dolnikowski; John S Millar; Chorthip Nartsupha; Daniel J Rader; P Hugh R Barrett; Margaret E Brousseau; Peter M Schaefer; Megan L Wolfe; Ernst J Schaefer
Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.
Journal of lipid research 2012;53(6):1190-9.
2009: Margaret E Brousseau; John S Millar; Margaret R Diffenderfer; Chorthip Nartsupha; Bela F Asztalos; Megan L Wolfe; James P Mancuso; Andres G Digenio; Daniel J Rader; Ernst J Schaefer
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.
Journal of lipid research 2009;50(7):1456-62.
2008: John S Millar; Margaret E Brousseau; Margaret R Diffenderfer; Hugh Barrett; Francine K Welty; Jeffrey S Cohn; Aisha Wilson; Megan L Wolfe; Chorthip Nartsupha; Peter M Schaefer; Andres G Digenio; James P Mancuso; Gregory G Dolnikowski; Ernst Schaefer; Daniel J Rader
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
Journal of lipid research 2008;49(3):543-9.
2007: Angeliki Georgopoulos; Hanna E Bloomfield; Dorothea Collins; Margaret E Brousseau; Jose Ordovas; John J O'Connor; Sander J Robins; Ernst Schaefer
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Atherosclerosis 2007;194(1):169-74.
2006: E Shyong Tai; Dorothea Collins; Sander J Robins; John J O'Connor; Hanna E Bloomfield; Jose Ordovas; Ernst Schaefer; Margaret E Brousseau
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Atherosclerosis 2006;187(1):153-60.
2006: John S Millar; Margaret E Brousseau; Margaret R Diffenderfer; Hugh Barrett; Francine K Welty; Aisha Faruqi; Megan L Wolfe; Chorthip Nartsupha; Andres G Digenio; James P Mancuso; Gregory G Dolnikowski; Ernst Schaefer; Daniel J Rader
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(6):1350-6.
2005: Margaret E Brousseau
Emerging role of high-density lipoprotein in the prevention of cardiovascular disease.
Drug discovery today 2005;10(16):1095-101.
2005: Kouji Kajinami; Margaret E Brousseau; Jose Ordovas; Ernst Schaefer
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Atherosclerosis 2005;180(2):407-15.
2005: Margaret E Brousseau; Margaret R Diffenderfer; John S Millar; Chorthip Nartsupha; Bela F Asztalos; Francine K Welty; Megan L Wolfe; Mats Rudling; Ingemar Björkhem; Bo Angelin; James P Mancuso; Andres G Digenio; Daniel J Rader; Ernst Schaefer
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(5):1057-64.
2005: Kouji Kajinami; Margaret E Brousseau; Stefania Lamon-Fava; Jose Ordovas; Ernst Schaefer
Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.
Atherosclerosis 2005;178(2):331-8.
2004: Kouji Kajinami; Noboru Takekoshi; Margaret E Brousseau; Ernst Schaefer
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
Atherosclerosis 2004;177(2):219-34.
2004: Margaret E Brousseau
Common variation in genes involved in HDL metabolism influences coronary heart disease risk at the population level.
Reviews in endocrine & metabolic disorders 2004;5(4):343-9.
2004: Marcelo C Batista; Francine K Welty; Margaret R Diffenderfer; Mark J Sarnak; Ernst Schaefer; Stefania Lamon-Fava; Bela F Asztalos; Gregory G Dolnikowski; Margaret E Brousseau; Julian B Marsh
Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
Metabolism: clinical and experimental 2004;53(10):1255-61.
2004: Margaret E Brousseau; Allison L Goldkamp; Dorothea Collins; Serkalem Demissie; Allison C Connolly; L Adrienne Cupples; Jose Ordovas; Hanna E Bloomfield; Sander J Robins; Ernst Schaefer
Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial.
Journal of lipid research 2004;45(10):1885-91.
2004: Kouji Kajinami; Margaret E Brousseau; Jose Ordovas; Ernst Schaefer
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Atherosclerosis 2004;175(2):287-93.
2004: Kouji Kajinami; Margaret E Brousseau; Jose Ordovas; Ernst Schaefer
Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.
The American journal of cardiology 2004;93(8):1046-50.
2004: Margaret E Brousseau; Ernst Schaefer; Megan L Wolfe; LeAnne T Bloedon; Andres G Digenio; Ronald W Clark; James P Mancuso; Daniel J Rader
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
The New England journal of medicine 2004;350(15):1505-15.
2004: Kouji Kajinami; Margaret E Brousseau; Chorthip Nartsupha; Jose Ordovas; Ernst Schaefer
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Journal of lipid research 2004;45(4):653-6.
2004: Kouji Kajinami; Margaret E Brousseau; Jose Ordovas; Ernst Schaefer
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
The American journal of cardiology 2004;93(1):104-7.
2002: Margaret E Brousseau; John J O'Connor; Jose Ordovas; Dorothea Collins; James D Otvos; Tatyana Massov; Judith R McNamara; Hanna Bloomfield Rubins; Sander J Robins; Ernst Schaefer
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(7):1148-54.
2001: Ernst Schaefer; Margaret E Brousseau; Margaret R Diffenderfer; J S Cohn; Francine K Welty; J O'Connor; Gregory G Dolnikowski; J Wang; R A Hegele; P J Jones
Cholesterol and apolipoprotein B metabolism in Tangier disease.
Atherosclerosis 2001;159(1):231-6.
2001: Bela F Asztalos; Margaret E Brousseau; Judith R McNamara; Katalin V Horvath; Paul S Roheim; Ernst Schaefer
Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease.
Atherosclerosis 2001;156(1):217-25.
2001: Margaret E Brousseau; Marek Bodzioch; Ernst Schaefer; Allison L Goldkamp; Danuta Kielar; M Probst; Jose Ordovas; Charalampos Aslanidis; Karl J Lackner; Hanna Bloomfield Rubins; Dorothea Collins; Sander J Robins; P W Wilson; Gerd Schmitz
Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease.
Atherosclerosis 2001;154(3):607-11.
2000: Margaret E Brousseau; GP Eberhart; J Dupuis; Bela F Asztalos; Allison L Goldkamp; Ernst Schaefer; Mason W Freeman
Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size.
Journal of lipid research 2000;41(7):1125-35.
2000: Margaret E Brousseau; Ernst Schaefer; J Dupuis; B Eustace; P Van Eerdewegh; Allison L Goldkamp; L M Thurston; M G FitzGerald; D Yasek-McKenna; G O'Neill; GP Eberhart; B Weiffenbach; Jose Ordovas; Mason W Freeman; R H Brown; J Z Gu
Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds.
Journal of lipid research 2000;41(3):433-41.